Danaher to Acquire Medical Device Maker Masimo for $180 Per Share Cash

Danaher Corporation (NYSE: DHR) announced on February 17, 2026, that it has entered into a definitive agreement to acquire Masimo Corporation, a leading medical technology company specializing in patient monitoring solutions, for $180 per share in an all-cash transaction.

The Change

The acquisition represents a significant expansion of Danaher's medical technology portfolio through the addition of Masimo's innovative patient monitoring and sensor technologies. Under the terms of the merger agreement dated February 16, 2026, Danaher will acquire all outstanding shares of Masimo common stock for $180 per share in cash, without interest.

The transaction structure involves Mobius Merger Sub, Inc., a wholly-owned subsidiary of Danaher, merging with and into Masimo. Following the merger's completion, Masimo will continue as a surviving corporation and operate as a wholly-owned subsidiary of Danaher.

The deal remains subject to customary closing conditions, including expiration of the Hart-Scott-Rodino antitrust waiting period and receipt of certain non-U.S. antitrust and foreign direct investment approvals. Masimo shareholders will need to approve the transaction at a special meeting, with the company planning to file proxy materials with the Securities and Exchange Commission.

Background

Danaher Corporation, a global science and technology innovator, has built a diverse portfolio of leading brands across life sciences, diagnostics, and environmental solutions. With a market presence spanning multiple continents, Danaher has consistently pursued strategic acquisitions to strengthen its position in high-growth markets, particularly in healthcare and medical technology.

The company's acquisition strategy has historically focused on businesses that complement its existing platforms while providing opportunities for operational improvements through the Danaher Business System. This disciplined approach to M&A has enabled Danaher to build leadership positions across its core segments.

Masimo Corporation has established itself as a pioneer in noninvasive patient monitoring technologies, with its pulse oximetry and patient monitoring solutions deployed in hospitals worldwide. The company's innovative sensor technologies and signal processing capabilities have set industry standards for patient care, particularly in critical care and perioperative settings.

What It Means

This acquisition signals Danaher's continued commitment to expanding its presence in the medical technology sector, particularly in patient monitoring and diagnostic solutions. The addition of Masimo's technologies could enhance Danaher's ability to serve healthcare providers with integrated solutions across the care continuum.

For Danaher, the acquisition brings advanced sensor technologies and signal processing expertise that could create synergies with its existing diagnostic and life sciences platforms. The combination may accelerate innovation in connected healthcare solutions and data analytics, areas increasingly critical to modern healthcare delivery.

The all-cash structure of the transaction demonstrates Danaher's financial strength and confidence in Masimo's strategic value. The deal pricing at $180 per share represents a premium that reflects both Masimo's market position and its growth potential within Danaher's portfolio.

From an operational perspective, Masimo's integration into Danaher could benefit from the Danaher Business System, the company's continuous improvement methodology that has historically driven operational excellence across acquired businesses. This could potentially enhance Masimo's manufacturing efficiency, product quality, and customer service capabilities.

The transaction's completion timeline will depend on regulatory approvals and shareholder consent, with both companies working to satisfy closing conditions. Given the complementary nature of the businesses and limited product overlap, the regulatory review process may focus primarily on ensuring continued market competition and innovation in patient monitoring technologies.

For the broader medical technology industry, this acquisition underscores ongoing consolidation trends as companies seek scale and technological capabilities to address evolving healthcare needs. The combination of Danaher's global reach and Masimo's specialized technologies could influence competitive dynamics in patient monitoring markets.